Sairiyo..to be IPO, See Link belowPartner PharmaTher (PHRM) 49% owner to take Sairiyo Subsidiary public in Q4..and has option to acquire up 90% as per their Financing Agreement of last July 2023. See PharmaTher Investor presentation just updated for August-24. This will provide much upside and valuation for both PharmaDrug and PharmaTher investors/shareholders once completed, and shareholds would receive free shares of that IPO spin-out . Upside potential not only with IPO also with their first in kind trial for Cep PD001 reformulated drug approved to commence Phase 1 trials, then commence application to FDA phase 2 and 3 trials in U.S.
High-lite link below: Enjoy!
https://www.pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf